Could imatinib replace surgery in esophageal gastrointestinal stromal tumor

Saudi Medical Journal

Volumn 27, Issue 8, 2006, Pages 1236-1239

  Al Salam, Suhail N ^a   El Teraifi, Hassan A ^b   Taha, Mazen S ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b TAWAM HOSPITAL   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CD34 ANTIGEN; IMATINIB; PROTEIN S 100; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR RECEPTOR; VIMENTIN; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; ESOPHAGUS SURGERY; ESOPHAGUS TUMOR; FOLLOW UP; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; TUMOR LOCALIZATION; TUMOR VOLUME; MIDDLE AGED; PATHOLOGY;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 34447250576     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002; 33: 669-676.
2. Trupiano JK, Stewart RE, Misick C, Appelman HD, Goldblum JR. Gastric stromal tumors: A clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors. Am J Surg Pathol 2002; 26: 705-714.
3. Iijima S, Maesawa C, Sato N, Ikeda K, Inaba T, Akiyama Y, et al. Gastrointestinal stromal tumor of the esophagus: Significance of immunohistochemical and genetic analyses of the c-kit gene. Eur J Gastroenterol Hepatol 2002; 14: 445-448.
4. Mikhael AI, Bacchi CE, Zarbo RJ, Ma CK, Gown AM. CD34-expression in stromal tumors of the gastrointestinal tract. Appl Immunohistochem 1994; 2: 89-93.
5. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of Cajal as precursors for gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377-389.
6. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
7. Sarlomo-Rikala M, Kovatich A, Barusevicius A, Miettinen M. CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728-734.
8. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710
9. Miettine MM, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68.
10. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20-21 march 2004 under the auspices of ESMO. Ann Oncol 2005; 16: 566-578.